Walvax Biotechnology Co., Ltd. (SHE:300142)
China flag China · Delayed Price · Currency is CNY
12.97
-0.04 (-0.31%)
Sep 16, 2026, 3:04 PM CST

Walvax Biotechnology Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
2,0882,4132,8044,1065,0793,452
Other Revenue
10.155.7217.867.927.6510.5
2,0982,4182,8214,1145,0863,463
Revenue Growth
-17.47%-14.29%-31.41%-19.12%46.89%17.82%
Cost of Revenue
508.54631.8742.2749.39673.14403.54
Gross Profit
1,5901,7862,0793,3644,4133,059
Selling, General & Admin
1,1101,2451,3991,8172,3021,636
Research & Development
279.03291.81595.77776.43922.25616.36
Other Operating Expenses
0.66-3.46-4.12-10016.4819.83
Operating Expenses
1,4011,6822,0552,5333,2392,267
Operating Income
188.83104.3324.01831.051,174792.22
Interest Expense
-17.14-0.91-8.43-5.95-7.11-5.77
Interest & Investment Income
37.6569.7866.7581.3581.82103.29
Currency Exchange Gain (Loss)
-10.03-2.634.053.060.82-0.22
Other Non Operating Income (Expenses)
2.152.34169.74-63.64-75.3933.88
EBT Excluding Unusual Items
201.46172.91256.12845.861,174923.4
Gain (Loss) on Sale of Investments
-42.0729.68-98.34-234.75-199.33-280.74
Gain (Loss) on Sale of Assets
0.30.08-1.77-0.83-0.380.23
Asset Writedown
-4.92-88.25-7.68-11.31-1.66-5.11
Other Unusual Items
70.4551.6936.17-97.871.15
Pretax Income
223.28166.11184.5598.981,070708.95
Income Tax Expense
45.0940.9610.187.65132.24107.59
Earnings From Continuing Operations
178.19125.16174.4511.33938.23601.35
Net Income to Company
178.19125.16174.4511.33938.23601.35
Minority Interest in Earnings
10.5852.58-32.24-91.93-209.57-173.6
Net Income
188.77177.74142.16419.39728.65427.75
Net Income to Common
188.77177.74142.16419.39728.65427.75
Net Income Growth
1178.90%25.03%-66.10%-42.44%70.35%-57.36%
Shares Outstanding (Basic)
1,6091,6001,5991,6001,6031,569
Shares Outstanding (Diluted)
1,6091,6001,5991,6001,6041,573
Shares Change
1.20%0.05%-0.06%-0.21%1.93%0.90%
EPS (Basic)
0.120.110.090.260.450.27
EPS (Diluted)
0.120.110.090.260.450.27
EPS Growth
1163.86%24.97%-66.08%-42.32%67.12%-57.74%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
18.43-18.62486.49188.25110.31-398.21
Free Cash Flow Per Share
0.01-0.010.300.120.07-0.25
Dividend Per Share
0.1250.1550.0100.0100.0100.027
Dividend Growth
212.50%1450.00%0%0%-62.96%-61.43%
Gross Margin
75.76%73.87%73.69%81.78%86.77%88.35%
Operating Margin
9.00%4.31%0.85%20.20%23.08%22.88%
Profit Margin
9.00%7.35%5.04%10.20%14.32%12.35%
Free Cash Flow Margin
0.88%-0.77%17.24%4.58%2.17%-11.50%
EBITDA
542.75485.6387.611,1211,422927.65
EBITDA Margin
25.87%20.08%13.74%27.25%27.96%26.79%
D&A For EBITDA
353.92381.28363.59289.97248.4135.43
EBIT
188.83104.3324.01831.051,174792.22
EBIT Margin
9.00%4.31%0.85%20.20%23.08%22.88%
Effective Tax Rate
20.19%24.65%5.48%14.63%12.35%15.18%
Revenue as Reported
2,0982,4182,8214,1145,086-
Advertising Expenses
-28.2842.6678.0194.8324.15